TrialPsychopharmacology2016

A phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-063, a selective PDE10A inhibitor.

Max Tsai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.